Jaguar Health’s price hike questioned by Democrats

House Oversight and Reform Chairwoman Carolyn B. Maloney, D-N.Y., sent a letter to Jaguar Health Inc. on Monday chiding the drugmaker for tripling the price of a medication that could be used with potential coronavirus treatments and demanding copies of the company’s internal communications about the increase.

The drug, Mytesi, can be used to alleviate gastrointestinal side effects that can often accompany the use of antiviral medicine. The Centers for Disease Control and Prevention issued guidance that identified the drug as a possible treatment for side effects from antiviral prescriptions that could be used to treat COVID-19, according to Maloney’s letter, which was also signed by Rep. Jackie Speier, D-Calif.

“The timing of Jaguar’s price increase raises questions about whether this decision was connected with the company’s expectation that it eventually could market Mytesi to treat coronavirus patients,” the members wrote in the May 4 letter that urged the drug manufacturer to “reverse this drastic price increase.”

Read More.